406 related articles for article (PubMed ID: 7519727)
1. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
2. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Jones NJ; Ellard S; Waters R; Parry EM
Carcinogenesis; 1993 Dec; 14(12):2487-94. PubMed ID: 8269616
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
6. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
7. Mutagenic properties of topoisomerase-targeted drugs.
Baguley BC; Ferguson LR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):213-22. PubMed ID: 9748584
[TBL] [Abstract][Full Text] [Related]
8. Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells.
Aratani Y; Andoh T; Koyama H
Mutat Res; 1996 Feb; 362(2):181-91. PubMed ID: 8596537
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster.
Sortibrán AN; Téllez MG; Rodríguez-Arnaiz R
Mutat Res; 2006 Apr; 604(1-2):83-90. PubMed ID: 16529987
[TBL] [Abstract][Full Text] [Related]
10. Mutagenicity and clastogenicity of teniposide (VM-26) in L5178Y/TK +/- -3.7.2C mouse lymphoma cells.
DeMarini DM; Brock KH; Doerr CL; Moore MM
Mutat Res; 1987 Mar; 187(3):141-9. PubMed ID: 3821767
[TBL] [Abstract][Full Text] [Related]
11. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.
Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM
Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833
[TBL] [Abstract][Full Text] [Related]
12. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs.
Degrassi F; Fiore M; Palitti F
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):317-25. PubMed ID: 15281904
[TBL] [Abstract][Full Text] [Related]
14. Deletion and duplication sequences induced in CHO cells by teniposide (VM-26), a topoisomerase II targeting drug, can be explained by the processing of DNA nicks produced by the drug-topoisomerase interaction.
Ripley LS
Mutat Res; 1994 Apr; 312(2):67-78. PubMed ID: 7510833
[TBL] [Abstract][Full Text] [Related]
15. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
16. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo.
Mukherjee A; Sen S; Agarwal K
Mutat Res; 1993 Feb; 301(2):87-92. PubMed ID: 7678175
[TBL] [Abstract][Full Text] [Related]
18. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
19. Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase.
DeMarini DM; Doerr CL; Meyer MK; Brock KH; Hozier J; Moore MM
Mutagenesis; 1987 Sep; 2(5):349-55. PubMed ID: 2830452
[TBL] [Abstract][Full Text] [Related]
20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
